Search
Back 

NRG-GU002

NRG-GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Principal Investigator

Mark Hurwitz, MD

Primary Objective

To assess the benefit of docetaxel as measured by improvement in freedom from progression (phase II) and subsequently metastasis free survival (phase III) when given in combination with radiation and androgen deprivation in treatment of high risk prostate cancer post-radical prostatectomy

Patient Population

Pathologically proven diagnosis of adenocarcinoma of the prostate as confirmed at time of prostatectomy. Post prostatectomy Gleason ≥ 7, baseline PSA nadir ≥ 0.2 ng/ml. Surgical FFPE specimen must be submitted to GenomeDx for genomic analysis on DECIPHER GRID platform per Section 10 of the protocol.

Target Accrual

297 (phase II), 612 (phase III)

Status

December 30, 2016

Protocol Documents

  • EMR Pilot template and procedure letter are available are available at NRG-GU002
  • The protocol and related documents are available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

The protocol and related documents are available at NRG-BN001
The protocol and related documents are available at NRG-BN001

Copyright 2017 by NRG Oncology